HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress

Cell Cycle

Volumn 15, Issue 16, 2016, Pages 2174-2182

  Coudre, Clémence ^a   Alani, Julien ^a   Ritchie, William ^b   Marsaud, Véronique ^c   Sola, Brigitte ^a   Cahu, Julie ^a  

^a UNIVERSITÉ DE CAEN   (France)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Centre National de la Recherche Scientifique   (France)

Author keywords

cancer stem like cell; cell cycle arrest; DNA damage response; DNA repair; irradiation; mTOR; senescence

Indexed keywords

DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; RAD50 PROTEIN; RAPAMYCIN;

ARTICLE; CELL STRESS; CONTROLLED STUDY; DNA STRAND BREAKAGE; DOWN REGULATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; IRRADIATION; MULTIPLE MYELOMA CELL LINE; NUCLEOTIDE SEQUENCE;

EID: 84978524194     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2016.1196302     Document Type: Article

References (51)

1. A.Gozzetti, V.Candi, G.Papini, M.Bocchia. Therapeutic advancements in multiple myeloma. Front Oncol 2014; 4:241-5; PMID:25237651; http://dx.doi.org/10.3389/fonc.2014.00241
2. C.Röllig, S.Knop, M.Bornhäuser. Multiple myeloma. Lancet 2015; 385:2197-208; PMID:25540889; http://dx.doi.org/10.1016/S0140-6736(14)60493-1
3. N.Mimura, T.Hideshima, K.C.Anderson. Novel therapeutic strategies for multiple myeloma. Exp Hematol 2015; 43:732-41; PMID:26118499; http://dx.doi.org/10.1016/j.exphem.2015.04.010
4. R.Franqui-Machin, E.B.Wendlandt, S.Janz, F.Zhan, G.Tricot. Cancer stem cells are the cause of drug resistance in multiple myeloma:fact or fiction? Oncotarget 2015; 6:40496-506; PMID:26415231
5. L.Pilarski, K.Seeberger, R.Coupland, A.Eshpeter, J.Keats, B.Taylor, A.R.Belch. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol 2002; 30:221-8; PMID:11882359; http://dx.doi.org/10.1016/S0301-472X(01)00788-3
6. W.Matsui, C.A.Huff, Q.Wang, M.T.Malehorn, J.Barber, Y.Tanhehco, B.D.Smith, C.I.Civin, R.J.Jones. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103:2332-6; PMID:14630803; http://dx.doi.org/10.1182/blood-2003-09-3064
7. W.Matsui, Q.Wang, J.P.Barber, S.Brennan, B.D.Smith, I.Borrello, I.McNiece, L.Lin, R.F.Ambinder, C.Peacock, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68:190-7; PMID:18172311; http://dx.doi.org/10.1158/0008-5472.CAN-07-3096
8. R.Reghunathan, C.Bi, S.C.Liu, K.E.Loong, T.H.Chung, G.Huang, W.J.Chng. Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival. Oncotarget 2013; 4(8):1230-40; PMID:23985559; http://dx.doi.org/10.18632/oncotarget.1145
9. W.Zhou, Y.Yang, Z.Gu, H.Wang, J.Xia, X.Wu, X.Zhan, D.Levasseur, Y.Zhou, S.Janz, et al. ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma. Leukemia 2014; 28:1155-8; PMID:24365790; http://dx.doi.org/10.1038/leu.2013.383
10. Z.Chen, R.Z.Orlowski, M.Wang, L.Kwak, N.McCarty. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 2014; 123:2204-8; PMID:24425802; http://dx.doi.org/10.1182/blood-2013-07-517136
11. N.Hosen, Y.Matsuoka, S.Kishida, J.Nakata, Y.Mizutani, K.Hasegawa, A.Mugitani, H.Ichihara, Y.Aoyama, S.Nishida, et al. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia 2012; 26:2135-41; PMID:22430638; http://dx.doi.org/10.1038/leu.2012.80
12. D.Kim, C.Y.Park, B.C.Medeiros, I.L.Weissman. CD19-CD45low/-CD38hig/CD138+plasma cells enrich for human tumorigenic myeloma cells. Leukemia 2012; 26:2530-7; PMID:22733078; http://dx.doi.org/10.1038/leu.2012.140
13. J.Jakubikova, S.Adamia, M.Kost-Alimova, S.Klippel, D.Cervi, J.F.Daley, D.Cholujova, S.Y.Kong, M.Leiba, S.Blotta, et al. Lenalidomide targets clonogenic side population in multiple myeloma:pathophysiologic and clinical implications. Blood 2011; 117:4409-19; PMID:21321360; http://dx.doi.org/10.1182/blood-2010-02-267344
14. A.Chaidos, C.P.Barnes, G.Cowan, P.C.May, V.Melo, E.Hatjiharissi, M.Papaioannou, H.Harrington, H.Doolittle, E.Terpos, et al. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood 2013; 121:318-28; PMID:23169779; http://dx.doi.org/10.1182/blood-2012-06-436220
15. E.Van Valckenborgh, W.Matsui, P.Agarwal, S.Lub, X.Dehui, E.De Bruyne, E.Menu, C.Empsen, L.van Grunsven, J.Agarwal, et al. Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model. Leukemia 2012; 26:1436-9; PMID:22289925; http://dx.doi.org/10.1038/leu.2011.373
16. J.Cahu, S.Bustany, B.Sola. Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells. Cell Death Dis 2012; 3:e446; PMID:23254289; http://dx.doi.org/10.1038/cddis.2012.183
17. C.D.Schlaff, A.Krauze, A.Belard, J.J.O.Connell, K.A.Camphausen. Bringing the heavy:carbon ion therapy in the radiobiological and clinical context. Radiat Oncol 2014; 9:88; PMID:24679134; http://dx.doi.org/10.1186/1748-717X-9-88
18. N.J.Curtin. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012; 12:801-17; PMID:23175119; http://dx.doi.org/10.1038/nrc3399
19. J.Campisi. Aging, cellular senescence, and cancer. Annu Rev Physiol 2013; 75:685-705; PMID:23140366; http://dx.doi.org/10.1146/annurev-physiol-030212-183653
20. S.N.Garcia, O.Pereira-Smith. MRGing chromatin dynamics and cellular senescence. Cell Biochem Biophys 2008; 50:133-41; PMID:18231726; http://dx.doi.org/10.1007/s12013-008-9006-7
21. L.Yang, T.Song, L.Chen, H.S.J.Chen. Nucleolar repression facilitates initiation and maintenance of senescence. Cell Cycle 2015; 14:3613-23; PMID:26505814; http://dx.doi.org/10.1080/15384101.2015.1100777
22. C.L.Brooks, W.Gu. How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 2009; 9:123-8; PMID:19132007; http://dx.doi.org/10.1038/nrc2562
23. E.J.Kim, S.J.Um. SIRT1:roles in aging and cancer. BMB Reports 2008; 41:751-6; PMID:19017485; http://dx.doi.org/10.5483/BMBRep.2008.41.11.751
24. T.H.Stracker, J.H.J.Petrini. The MRE11 complex:starting from the ends. Nat Rev Mol Cell Biol 2011; 12:90-103; PMID:21252998; http://dx.doi.org/10.1038/nrm3047
25. S.K.Martin, P.Diamond, S.Gronthos, D.J.Peet, A.C.W.Zannettino. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 2011; 25:1533-42; PMID:21637285; http://dx.doi.org/10.1038/leu.2011.122
26. B.J.Moeller, M.R.Dreher, Z.N.Rabbani, T.Schroeder, Y.Cao, C.Y.Li, M.W.Dewhirst. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005; 8:99-110; PMID:16098463; http://dx.doi.org/10.1016/j.ccr.2005.06.016
27. O.V.Leontieva, V.Natarajan, Z.N.Demidenko, L.G.Burdelya, A.V.Gudkov, M.V.Blagosklonny. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci USA 2012; 109:13314-8; PMID:22847439; http://dx.doi.org/10.1073/pnas.1205690109
28. O.V.Leontieva, M.V.Blagosklonny. Hypoxia and gerosuppression:the mTOR saga continues. Cell Cycle 2012; 11:3926-31; PMID:22987149; http://dx.doi.org/10.4161/cc.21908
29. O.V.Leontieva, Z.N.Demidenko, M.V.Blagosklonny. S6K in geroconversion. Cell Cycle 2013; 12:3063-9; PMID:23974099; http://dx.doi.org/10.4161/cc.26130
30. T.Strömberg, A.Dimberg, A.Hammarberg, K.Carlson, A.Österborg, K.Nilsson, H.Jernberg-Wiklund. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 2004; 103:3138-3147; PMID:15070696; http://dx.doi.org/10.1182/blood-2003-05-1543
31. P.Frost, Y.Shi, B.Hoang, J.Gera, A.Lichenstein. Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors:rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin. Mol Cancer Ther 2009; 8:83-93; PMID:19139116; http://dx.doi.org/10.1158/1535-7163.MCT-08-0254
32. C.Gourzones-Dmitriev, A.Kassambara, S.Sahota, T.Rème, J.Moreaux, P.Bourquard, D.Hose, P.Pasero, A.Constantinou, B.Klein. DNA repair pathways in human multiple myeloma. Cell Cycle 2014; 12:2760-73; http://dx.doi.org/10.4161/cc.25951
33. C.A.Cremona, A.Behrens. ATM signalling and cancer. Oncogene 2013; 33:3351-60; PMID:23851492; http://dx.doi.org/10.1038/onc.2013.275
34. A.B.Herrero, J.F.San-Miguel, N.C.Gutierrez. Deregulation of DNA double-strand break repair in multiple myeloma:implications for genome stability. PLOS One 2015; 10:e0121581; PMID:25790254; http://dx.doi.org/10.1371/journal.pone.0121581
35. S.Jirawatnotai, Y.Hu, W.Michowski, J.E.Elias, L.Becks, F.Bienvenu, A.Zagozdzon, T.Goswami, Y.E.Wang, A.B.Clark, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 2011; 474:230-4; PMID:21654808; http://dx.doi.org/10.1038/nature10155
36. B.Sola, X.Troussard. Relevance of cyclin D1 level in the pathogenesis of multiple myeloma. Blood 2003; 102:4245-6; PMID:14623774; http://dx.doi.org/10.1182/blood-2003-07-2486
37. R.Fonseca, P.L.Bergsagel, J.Drach, J.Shaughnessy, N.Gutierrez, A.K.Stewart, G.Morgan, B.Van Ness, M.Chesi, S.Minvielle, et al. International myeloma working group molecular classification of multiple myeloma:spotlight review. Leukemia 2009; 23:2210-21; PMID:19798094; http://dx.doi.org/10.1038/leu.2009.174
38. T.Chandra, P.A.Ewels, S.Schoenfelder, M.Furlan-Magaril, S.W.Wingett, K.Kirschner, J.Y.Thuret, S.Andrews, P.Fraser, W.Reik. Global reorganization of the nuclear landscape in senescent cells. Cell Rep 2015; 10:471-83; PMID:25640177; http://dx.doi.org/10.1016/j.celrep.2014.12.055
39. A.Corpet, M.Stucki. Chromatin maintenance and dynamics in senescence:a spotlight on SAHF formation and the epigenome of senescent cells. Chromosoma 2014; 123:423-36; PMID:24861957; http://dx.doi.org/10.1007/s00412-014-0469-6
40. Y.Wang, Y.Liang, P.M.Vanhoutte. SIRT1 and AMPK in regulating mammalian senescence:a critical review and a working model. FEBS Lett 2011; 585:986-94; PMID:21130086; http://dx.doi.org/10.1016/j.febslet.2010.11.047
41. B.G.Childs, D.J.Baker, J.L.Kirkland, J.Campisi, J.M.van Deursen. Senescence and apoptosis:dueling or complementary cell fates? EMBO Rep 2014; 15:1139-53; PMID:25312810; http://dx.doi.org/10.15252/embr.201439245
42. T.Tchkonia, Y.Zhu, J.van Deursen, J.Campisi, J.L.Kirkland. Cellular senescence and the senescent secretory phenotype:therapeutic opportunities. J Clin Invest 2013; 123:966-72; PMID:23454759; http://dx.doi.org/10.1172/JCI64098
43. O.V.Leontieva, Z.N.Demidenko, M.V.Blagosklonny. Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program). Oncotarget 2015; 6:23238-48; PMID:26177051; http://dx.doi.org/10.18632/oncotarget.4836
44. P.Maiso, Y.Liu, B.Morgan, A.K.Azab, P.Ren, M.B.Martin, Y.Zhang, Y.Liu, A.Sacco, H.Ngo, et al. Defining the role of TORC1/2 in multiple myeloma. Blood 2011; 118:6860-70; PMID:22045983; http://dx.doi.org/10.1182/blood-2011-03-342394
45. N.E.Sharpless, C.J.Sherr. Forging a signature of in vivo senescence. Nat Rev Cancer 2015; 15:397-408; PMID:26105537; http://dx.doi.org/10.1038/nrc3960
46. M.E.Gallego, C.I.White. RAD50 function is essential for telomere maintenance in Arabidopsis. Proc Natl Acad Sci USA 2011; 98:1711-6; http://dx.doi.org/10.1073/pnas.98.4.1711
47. S.Le, J.K.Moore, J.E.Haber, C.W.Greider. RAD50 and RAD51 define two pathways that collaborate to maintain telomeres in the absence of telomerase. Genetics 1999; 152:143-52; PMID:10224249
48. M.Shiratsuchi, K.Muta, Y.Abe, S.Motomura, F.Taguchi, H.Takatsuki, N.Uike, T.Umemura, H.Nawata, J.Nishimura. Clinical significance of telomerase activity in multiple myeloma. Cancer 2002; 94:2232-8; PMID:12001122; http://dx.doi.org/10.1002/cncr.10472
49. H.D.Halicka, H.Zhao, J.Li, T.C.Hsieh, J.M.Wu, Z.Darzynkiewicz. Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling. Aging 2012; 4:952-65; PMID:23363784; http://dx.doi.org/10.18632/aging.100521
50. C.Laurent, A.Leduc, I.Pottier, V.Prévost, F.Sichel, J.L.Lefaix. Dramatic increase in oxidative stress in carbon-irradiated normal human skin fibroblasts. PLOS One 2013; 8:e85158; PMID:24376870; http://dx.doi.org/10.1371/journal.pone.0085158
51. T.D.Schmittgen, K.J.Livak. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008; 3:1101-8; PMID:18546601; http://dx.doi.org/10.1038/nprot.2008.73